Question 1

What is Alembic Pharmaceuticals?

Accepted Answer

Alembic Pharmaceuticals is a Company.

Question 2

How often does Alembic Pharmaceuticals appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 16 articles.

Question 3

When was Alembic Pharmaceuticals first tracked by Ergen?

Accepted Answer

First tracked on Jun 08, 2026.

Question 4

When was Alembic Pharmaceuticals last mentioned in news?

Accepted Answer

Last active on Jul 20, 2026.

Question 5

What is Alembic Pharmaceuticals's current news sentiment?

Accepted Answer

Aggregate sentiment score: 25 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Alembic Pharmaceuticals in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Alembic Pharmaceuticals?

Accepted Answer

Alembic NATCO get tentative USFDA approval for Olaparib (Jul 19, 2026, 6 articles).

Question 8

How did the "Alembic NATCO get tentative USFDA approval for Olaparib" event impact Alembic Pharmaceuticals?

Accepted Answer

Alembic will distribute the generic Olaparib in the US, expanding its oncology portfolio and addressing a $1.4B market. The tentative approval is a positive regulatory milestone, but commercial launch depends on litigation outcome.

Question 9

How did the "Waters Launches New Bioseparation Columns" event impact Alembic Pharmaceuticals?

Accepted Answer

Alembic Pharmaceuticals, through its Group Leader Ashish Kanhed, provided positive feedback on the performance of the new BioResolve Peptide RP Columns.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.